Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2016

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2016
Published Jul 27, 2016
75 pages — Published Jul 27, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2016, provides in depth analysis on Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted pipeline therapeutics.

The report provides comprehensive information on the Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)
- The report reviews Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics and enlists all their major and minor projects
- The report assesses Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targete

  
Source:
Document ID
GMDHC0408TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Overview81
Therapeutics Development94
  Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Products under Development by Stage of Development91
  Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Products under Development by Therapy Area101
  Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Products under Development by Indication112
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Pipeline Products Glance133
  Late Stage Products131
  Early Stage Products141
  Unknown Stage Products151
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Products under Development by Companies162
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Products under Development by Universities/Institutes182
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Therapeutics Assessment206
  Assessment by Monotherapy/Combination Products201
  Assessment by Mechanism of Action211
  Assessment by Route of Administration222
  Assessment by Molecule Type242
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Companies Involved in Therapeutics Development268
  Biogen, Inc.261
  BioMAS Ltd.271
  MedImmune, LLC281
  Merck &Co., Inc.291
  SciFluor Life Sciences, LLC301
  Tissue Therapies Limited311
  TWi Pharmaceuticals, Inc.321
  Vascular Pharmaceuticals, Inc.331
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Drug Profiles3423
  264-RAD Drug Profile341
  AC-301 Drug Profile351
  Antibodies to Inhibit AlphaVBeta6 for Oncology Drug Profile361
  AS-101 Drug Profile372
  BG-00011 Drug Profile391
  C-16Y Drug Profile401
  cilengitide Drug Profile412
  MK-0429 Drug Profile431
  OCU-200 Drug Profile441
  Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma Drug Profile451
  Proagio Drug Profile461
  RSF-201 Drug Profile471
  SF-0166 Drug Profile481
  Small Molecule to Antagonize AlphaVBetaI for Fibrosis Drug Profile491
  Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis Drug Profile501
  tetraiodothyroacetic acid Drug Profile511
  VF-001 Drug Profile521
  VF-002 Drug Profile531
  VF-003 Drug Profile541
  VF-004 Drug Profile551
  VPI-2690B Drug Profile561
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Dormant Projects575
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Discontinued Products622
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Featured News &Press Releases6410
  May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find641
  May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology651
  Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin av 3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease651
  Feb 11, 2016: Ocugen Announces Patent Allowance For Ocu-200661
  Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update661
  Feb 25, 2013: Merck Serono Announces Phase III Trial Of Cilengitide Did Not Meet Primary Endpoint In Patients With Newly Diagnosed Glioblastoma672
  Jun 09, 2011: Merck Serono Completes Patient Enrollment For Cilengitide s Pivotal Phase III Trial CENTRIC691
  Aug 31, 2010: Stromedix Receives FDA Orphan Drug Designation For STX-100 For Treatment Of Idiopathic Pulmonary Fibrosis691
  Jun 05, 2010: EMD Serono Announces Long-Term Follow-up Data From Cilengitide Study In Glioblastoma Patients701
  May 31, 2009: Study Shows Cilengitide Increased Overall Survival In Patients With Glioblastoma711
  Mar 16, 2009: Merck Serono Expands Cilengitide Development Program711
  Jan 22, 2009: Stromedix Secures Broad Patent Coverage For Lead Program, Including Compositions Related To Its Lead Product, STX-100721
  Aug 12, 2008: Stromedix Receives Orphan Drug Designation For STX-100 In Chronic Allograft Nephropathy721
  Jan 01, 2004:731
Appendix742
  Methodology741
  Coverage741
  Secondary Research741
  Primary Research741
  Expert Panel Validation741
  Contact Us741
  Disclaimer751

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2016" Jul 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Integrin-Alpha-V-Vitronectin-Receptor-Subunit-Alpha-or-CD51-or-ITGAV-Pipeline-Review-H2-2016-2088-16290>
  
APA:
Global Markets Direct - Market Research. (2016). Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2016 Jul 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Integrin-Alpha-V-Vitronectin-Receptor-Subunit-Alpha-or-CD51-or-ITGAV-Pipeline-Review-H2-2016-2088-16290>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.